Therapeutic application of tumour cell‐derived extracellular vesicles for drug‐resistant cancer therapy via interleukin 6/signal transducer and activator of transcription 3 signalling pathway
Clinical and Translational Discovery · 2022
DOI: 10.1002/ctd2.105 ↗At a glance
Journal article in Clinical and Translational Discovery, 2022. Written by Manqian Zhou and 2 co-authors. 8 references. The full text is freely available (open access, CC BY 4.0).
Abstract (original language)
Není k dispozici žádný abstrakt.
Cite
APA
Zhou, M., Wang, H., & Li, Z. (2022). Therapeutic application of tumour cell‐derived extracellular vesicles for drug‐resistant cancer therapy via interleukin 6/signal transducer and activator of transcription 3 signalling pathway. Clinical and Translational Discovery. https://doi.org/10.1002/ctd2.105
Vancouver
Zhou M, Wang H, Li Z. Therapeutic application of tumour cell‐derived extracellular vesicles for drug‐resistant cancer therapy via interleukin 6/signal transducer and activator of transcription 3 signalling pathway. Clinical and Translational Discovery. 2022. doi:10.1002/ctd2.105
BibTeX
@article{Zhou2022,
author = {Zhou, Manqian and Wang, Hui and Li, Zongjin},
title = {Therapeutic application of tumour cell‐derived extracellular vesicles for drug‐resistant cancer therapy via interleukin 6/signal transducer and activator of transcription 3 signalling pathway},
journal = {Clinical and Translational Discovery},
year = {2022},
doi = {10.1002/ctd2.105}
}
EUVIMED